The circadian nuclear receptor RORα negatively regulates cerebral ischemia-reperfusion injury and mediates the neuroprotective effects of melatonin

Biochim Biophys Acta Mol Basis Dis. 2020 Nov 1;1866(11):165890. doi: 10.1016/j.bbadis.2020.165890. Epub 2020 Jun 26.

Abstract

Disruptions of the circadian rhythm and reduced circulating levels of the circadian hormone melatonin predispose to ischemic stroke. Although the nuclear receptor RORα is considered as a circadian rhythm regulator and a mediator of certain melatonin effects, its potential role in cerebral ischemia-reperfusion (CI/R) injury and in the neuroprotective effects of melatonin remain undefined. Here, we observed that CI/R injury in RORα-deficient mice was associated with greater cerebral infarct size, brain edema, and cerebral apoptosis compared with wild-type model. In contrast, transgenic mice with brain-specific overexpression of RORα versus non-transgenic controls exerted significantly reduced infarct volume, brain edema and apoptotic response induced by CI/R. Mechanistically, RORα deficiency was found to exacerbate apoptosis pathways mediated by endoplasmic-reticulum stress and mitochondria and aggravate oxidative/nitrative stress after CI/R. Further studies revealed that RORα deficiency intensified the activation of nuclear factor-κB signaling induced by CI/R. Given the emerging evidence of RORα as an essential melatonin activity mediator, we further investigated the RORα roles in melatonin-exerted neuroprotection against acute ischemic stroke. Melatonin treatment significantly decreased infarct volume and cerebral apoptosis; mitigated endoplasmic reticulum stress and mitochondrial dysfunction; and inhibited CI/R injury-induced oxidative/nitrative stress and nuclear factor-κB activation, which was eradicated in RORα-deficient mice. Collectively, current findings suggest that RORα is a novel endogenous neuroprotective receptor, and a pivotal mediator of melatonin's suppressive effects against CI/R injury.

Keywords: Cerebral-protection; Ischemia reperfusion; Melatonin; Nuclear receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Apoptosis / drug effects
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / genetics
  • Brain Ischemia / metabolism*
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / genetics
  • Cerebral Infarction / metabolism
  • Circadian Rhythm / drug effects
  • Circadian Rhythm / genetics
  • Disease Models, Animal
  • Endoplasmic Reticulum Stress / drug effects
  • Male
  • Melatonin / therapeutic use*
  • Mice
  • Mice, Transgenic
  • Neuroprotective Agents / therapeutic use*
  • Nuclear Receptor Subfamily 1, Group F, Member 1 / genetics
  • Nuclear Receptor Subfamily 1, Group F, Member 1 / metabolism*
  • Oxidative Stress / drug effects
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / genetics
  • Reperfusion Injury / metabolism*
  • Signal Transduction / drug effects

Substances

  • Antioxidants
  • Neuroprotective Agents
  • Nuclear Receptor Subfamily 1, Group F, Member 1
  • Melatonin